To include your compound in the COVID-19 Resource Center, submit it here.

Nalmefene: Phase III data

Pooled data from 3 double-blind, placebo-controlled, European Phase III trials in about 2,000 patients showed that oral nalmefene led to a >=50% reduction in heavy drinking days, defined as >=5 drinks/day for

Read the full 322 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE